PROMIS NEUROSCIENCES INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
PROMIS NEUROSCIENCES INC. (PMN) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $0 as of 2022-12-31, per its 10-K filed 2023-03-08.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2023-03-08
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $0.00.
- 2022-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.84K.
- 2022-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $5.18K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-08 |
| 2022-09-30 | $4.84K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $5.18K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |